Cargando…

Utility of Repeated Praziquantel Dosing in the Treatment of Schistosomiasis in High-Risk Communities in Africa: A Systematic Review

BACKGROUND: Controversy persists about the optimal approach to drug-based control of schistosomiasis in high-risk communities. In a systematic review of published studies, we examined evidence for incremental benefits from repeated praziquantel dosing, given 2 to 8 weeks after an initial dose, in Sc...

Descripción completa

Detalles Bibliográficos
Autores principales:	King, Charles H., Olbrych, Stephanie K., Soon, Margaret, Singer, Mendel E., Carter, Jen, Colley, Daniel G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3176745/ https://www.ncbi.nlm.nih.gov/pubmed/21949893 http://dx.doi.org/10.1371/journal.pntd.0001321

Ejemplares similares

Environmental Predictors of Schistosomiasis Persistent Hotspots following Mass Treatment with Praziquantel
por: Walker, Joseph W., et al.
Publicado: (2020)

437. Spatial Distribution of Schistosomiasis After Repeated Praziquantel Treatments in a Rural Community in Brazil
por: Terashima, Rafael Ponce, et al.
Publicado: (2018)

Accuracy of the WHO praziquantel dose pole for large-scale community treatment of urogenital schistosomiasis in northern Mozambique: Is it time for an update?
por: Gazzinelli-Guimaraes, Pedro H., et al.
Publicado: (2018)

The Accuracy of Praziquantel Dose Poles for Mass Treatment of Schistosomiasis in School Girls in KwaZulu-Natal, South Africa
por: Baan, Marije, et al.
Publicado: (2016)

Factors associated with coverage of praziquantel for schistosomiasis control in the community-direct intervention (CDI) approach in Mali (West Africa)
por: Dabo, Abdoulaye, et al.
Publicado: (2013)

Praziquantel for the treatment of schistosomiasis during human pregnancy
por: Friedman, Jennifer F, et al.
Publicado: (2018)

Anaphylactic reaction to praziquantel following schistosomiasis treatment
por: Vasconcelos, Géssica Almeida, et al.
Publicado: (2023)

Defining Persistent Hotspots: Areas That Fail to Decrease Meaningfully in Prevalence after Multiple Years of Mass Drug Administration with Praziquantel for Control of Schistosomiasis
por: Kittur, Nupur, et al.
Publicado: (2017)

Efficacy of a low‐dose praziquantel and fenbendazole protocol in the treatment of asymptomatic schistosomiasis in dogs
por: Cridge, Harry, et al.
Publicado: (2021)

Efficacy of China-made praziquantel for treatment of Schistosomiasis haematobium in Africa: A randomized controlled trial
por: Wang, Xin-Yao, et al.
Publicado: (2019)

Bioorganometallic Compounds as Novel Drug Targets against Schistosomiasis in Sub-Saharan Africa: An alternative to Praziquantel?
por: Ndamse, Cuma Cumisa, et al.
Publicado: (2022)

Praziquantel Could Be the Appropriate Choice for the Diagnostic Treatment of Schistosomiasis
por: Fukuchi, Takahiko, et al.
Publicado: (2019)

Oxamniquine derivatives overcome Praziquantel treatment limitations for Schistosomiasis
por: Alwan, Sevan N., et al.
Publicado: (2023)

Persistent Hotspots in Schistosomiasis Consortium for Operational Research and Evaluation Studies for Gaining and Sustaining Control of Schistosomiasis after Four Years of Mass Drug Administration of Praziquantel
por: Kittur, Nupur, et al.
Publicado: (2019)

Effect of preventive chemotherapy with praziquantel on schistosomiasis among school-aged children in sub-Saharan Africa: a spatiotemporal modelling study
por: Kokaliaris, Christos, et al.
Publicado: (2022)

Single oral fixed-dose praziquantel-miltefosine nanocombination for effective control of experimental schistosomiasis mansoni
por: Eissa, Maha M., et al.
Publicado: (2020)

Repeated doses of Praziquantel in Schistosomiasis Treatment (RePST) – single versus multiple praziquantel treatments in school-aged children in Côte d’Ivoire: a study protocol for an open-label, randomised controlled trial
por: Hoekstra, P. T., et al.
Publicado: (2018)

Human Schistosomiasis Resistance to Praziquantel in China: Should We Be Worried?
por: Seto, Edmund Y. W., et al.
Publicado: (2011)

Evaluation of Artesunate and Praziquantel Combination Therapy in Murine Schistosomiasis mansoni
por: HEGAZY, Laila Abdel Moniem, et al.
Publicado: (2018)

Taste, A New Incentive to Switch to (R)-Praziquantel in Schistosomiasis Treatment
por: Meyer, Thorsten, et al.
Publicado: (2009)

Performance and Safety of Praziquantel for Treatment of Intestinal Schistosomiasis in Infants and Preschool Children
por: Sousa-Figueiredo, José C., et al.
Publicado: (2012)

Authors' Response to “Praziquantel Could Be the Appropriate Choice for the Diagnostic Treatment of Schistosomiasis”
por: Koizumi, Yohei, et al.
Publicado: (2019)

The Role of Praziquantel in the Prevention and Treatment of Fibrosis Associated with Schistosomiasis: A Review
por: Niu, Xuehua, et al.
Publicado: (2022)

Investigation on birth weight outcomes in schistosomiasis and praziquantel research: a correspondence
por: Holtfreter, Martha C., et al.
Publicado: (2023)

Praziquantel coverage in schools and communities targeted for the elimination of urogenital schistosomiasis in Zanzibar: a cross-sectional survey
por: Knopp, Stefanie, et al.
Publicado: (2016)

Schistosomiasis control in Senegal: results from community data analysis for optimizing preventive chemotherapy intervention with praziquantel
por: Diop, Boubacar, et al.
Publicado: (2023)

Inhibition of Granulomatous Inflammation and Prophylactic Treatment of Schistosomiasis with a Combination of Edelfosine and Praziquantel
por: Yepes, Edward, et al.
Publicado: (2015)

Combining Mechanochemistry and Spray Congealing for New Praziquantel Pediatric Formulations in Schistosomiasis Treatment
por: Albertini, Beatrice, et al.
Publicado: (2019)

Controlling schistosomiasis with praziquantel: How much longer without a viable alternative?
por: Bergquist, Robert, et al.
Publicado: (2017)

Immunomics-Guided Antigen Discovery for Praziquantel-Induced Vaccination in Urogenital Human Schistosomiasis
por: Pearson, Mark S., et al.
Publicado: (2021)

Praziquantel and Upper Gastrointestinal Bleeding in Hepatic Schistosomiasis: A Quasi-Experimental Study
por: Opio, Christopher Kenneth, et al.
Publicado: (2020)

Controlling Schistosomiasis: Significant Decrease of Anaemia Prevalence One Year after a Single Dose of Praziquantel in Nigerien Schoolchildren
por: Tohon, Zilahatou B., et al.
Publicado: (2008)

Treatment of schistosomiasis in African infants and preschool-aged children: downward extension and biometric optimization of the current praziquantel dose pole
por: Sousa-Figueiredo, José C., et al.
Publicado: (2012)

A Rapid Appraisal of Factors Influencing Praziquantel Treatment Compliance in Two Communities Endemic for Schistosomiasis in Côte d’Ivoire
por: Coulibaly, Jean T., et al.
Publicado: (2018)

Persistent Urogenital Schistosomiasis and Its Associated Morbidity in Endemic Communities within Southern Ghana: Suspected Praziquantel Resistance or Reinfection?
por: Tetteh-Quarcoo, Patience B., et al.
Publicado: (2020)

A diagnostic challenge for schistosomiasis japonica in China: consequences on praziquantel-based morbidity control
por: Zhou, Yi-biao, et al.
Publicado: (2011)

Cytokine Pattern of T Lymphocytes in Acute Schistosomiasis mansoni Patients following Treated Praziquantel Therapy
por: Silveira-Lemos, Denise, et al.
Publicado: (2013)

Development of the PraziCalc mobile device-app to calculate praziquantel dosage in the treatment of schistosomiasis
por: Viana, Agostinho Gonçalves, et al.
Publicado: (2018)

Elucidation of Cellular Responses in Non-human Primates With Chronic Schistosomiasis Followed by Praziquantel Treatment
por: Melkus, Michael W., et al.
Publicado: (2020)

Parasitological Observation in Schoolchildren with Urogenital Schistosomiasis Following Treatment with Three Different Brands of Praziquantel
por: Jin, Yan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jupk36rd4kspbjrfheaf0nsc3e